Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Trial Profile

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2018

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Acute coronary syndromes; Myocardial infarction; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPROVE-IT
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 04 Aug 2018 Results published in the American Journal of Cardiology.
    • 20 Dec 2017 Results published in the Circulation
    • 15 Nov 2017 Results of prespecified analysis assessing the relationship of cardiac biomarkers with the risk of recurrent cardiovascular events and the benefit of addition of ezetimibe to statin therapy presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top